SCIENTIFIC BACKGROUND

MVK

Category:

Mevalonate aciduria (MA) and hyper-IgD-and-periodic fever syndrome (HIDS) represent the two ends of the spectrum of clinical symptoms of mevalonate kinase deficiency (MKD). The severity of symptoms, in this case, depends on the remaining enzyme activity of mevalonate kinase; in HIDS it is approximately 10%, in MA <0.5%.

 

HIDS is one of the rare congenital periodic fever syndromes; a few hundred cases of HIDS are thought to occur worldwide. The disease is inherited in an autosomal recessive manner and almost exclusively manifests in early childhood, usually in the first year of life. Febrile episodes usually occur every 4-8 weeks and last approximately 3-7 days. In up to 50% of cases, they are triggered by certain factors, usually vaccinations, stress, and infections. The relapses are typically accompanied by cervical lymphadenopathy, arthritis/arthralgias, measles-like exanthema, and abdominal pain with diarrhea and vomiting. In most cases, the specific symptoms are preceded by severe headaches and chills. The development of amyloidosis is very rare. There is usually a continuous elevation of IgD (and IgA) serum concentrations above 100 IU/ml, but in about 20% of cases, especially in young children, IgD levels may be within the normal range. Currently, there are no approved guidelines for the treatment of HIDS. In addition to non-steroidal anti-inflammatory drugs, corticosteroids are initially used during febrile episodes. In severe courses of the disease, treatment with IL1 blockers seems to be most promising.

 

Symptoms of MA include psychomotor retardation, failure to thrive, progressive cerebellar ataxia, dysmorphia, progressive loss of vision, and recurrent fevers. Life expectancy is often limited.

 

Both diseases are caused by mutations in the MVK gene, which encodes mevalonate kinase, a key enzyme in cholesterol biosynthesis. The relationship between a defect in cholesterol biosynthesis and autoinflammatory disease pattern is still unclear. In about 80% of HIDS patients, the mutation V377I in exon 11 is present in a homozygous form or in combination with a second mutation.

 

References

Gattorno et al. 2019, Ann Rheum Dis 78:1025 / Martorana et al. 2017, Front Immunol 8:344 / van der Burgh et al. 2013, Clin Immunol 147:197 / Mandey et al. 2006, Hum Mut 27:796

GENES

MVK
How to order

LATEST ARTICLES

Have you ever wondered how jet-setting across the globe might affect your gut health? A recent study has dug into this intriguing question, revealing...

Read more

In June 2023, Medicover Genetics attended the 56th conference of the European Society of Human Genetics (ESHG) which took place in Glasgow, Scotland....

Read more

Vitamin D, also known as “the sunshine vitamin”, is a fat-soluble vitamin that helps the body absorb calcium and phosphate, which are essential f...

Read more

Every movement our body makes is controlled by a long, thin, tube-like structure called the “spinal cord”. The spinal cord is part of our nervous...

Read more

Genetic variant databases are vital for interpreting genetic variations in clinical settings and research. However, misclassified variants can create...

Read more

A recent article published by our team in the International Journal of Molecular Sciences [1], aimed to evaluate the prevalence, prognostic and predi...

Read more

A healthy, nutritious and well-balanced diet is always important for a person’s well-being, and it is even more so during pregnancy as the developi...

Read more

The sun is hot and you are sweating. Most of us know how it feels to sweat, and when we sweat. This is a normal bodily response to an increase in tem...

Read more

All about the pancreas The pancreas is a pear-shaped organ that is located at the upper left side of the abdomen, behind the stomach. It has two m...

Read more

The father of genetics is Gregor Mendel. Mendel was an Austrian monk, whose experiments breeding pea plants in the monastery garden led to breakthrou...

Read more